肺癌治疗新进展——靶向治疗篇 (老肿会).pptVIP

OS的主要分析 (N=795) 中位随访18.4个月 Soria JC, et al. 2015 ASCO Abstract 8002. 1.0 0.8 0.6 0.4 0.2 0 0 3 6 9 12 15 18 21 14 27 30 时间 (月) OS 28.2% 14.4% 36.4% 22.0% 阿法替尼N=398 厄洛替尼N=397 中位，月(95%CI) 7.9(7.2-8.7) 6.8(5.9-7.8) HR(95%CI) 0.81(0.69-0.95) P值 0.0077 LUX-Lung 7 A randomised, open-label, phase IIB trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation–positive advanced adenocarcinoma of the lung ARCHER 1050Randomized, Phase III study of dacomitinib versus gefitinib in NSCLC with EGFR mutation 1st generation vs 2nd generation Three generation EGFR-TKI 1st gener